Tarsus Pharmaceuticals (TARS) Capital Expenditures (2019 - 2026)

Tarsus Pharmaceuticals' Capital Expenditures history runs 8 years deep, the most recent figure standing at $5.8 million for Q1 2026.

• In Q1 2026, Capital Expenditures rose 14817.95% year-over-year to $5.8 million; the TTM figure through Mar 2026 stood at $15.6 million (up 873.72% YoY), while the FY2025 annual figure was $9.9 million, up 529.16% from the prior year.
• Capital Expenditures was $5.8 million for Q1 2026 at Tarsus Pharmaceuticals, down from $6.4 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $6.4 million in Q4 2025 to a low of -$1.4 million in Q4 2023.
• Historically, Capital Expenditures has averaged $1.1 million across 5 years, with a median of $312500.0 in 2022.
• The sharpest annual moves came in 2023 and 2026: Capital Expenditures plunged 282.12% in 2023, then jumped 14817.95% in 2026.
• A 5-year view of Capital Expenditures shows it stood at -$358000.0 in 2022, then slumped by 282.12% to -$1.4 million in 2023, then surged by 105.26% to $72000.0 in 2024, then surged by 8730.56% to $6.4 million in 2025, then fell by 8.49% to $5.8 million in 2026.
• The last three Capital Expenditures figures came in at $5.8 million (Q1 2026), $6.4 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.